enGene Incorporated, based in Vancouver, BC, has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others. The Company has achieved impressive pre-clinical efficacy results utilizing the gastrointestinal (GI) mucosal cells to induce expression of therapeutic proteins in two common, chronic diseases: localized delivery of the anti- inflammatory cytokine IL-10 to the colon for treating inflammatory bowel disease (IBD); and Proof-of-concept has been established for several additional applications, including siRNA delivery to various tissues to suppress expression of disease-causing proteins. The Company has an extensive patent library on the compositions, methods and manufacturing processes for its technologies. Additionally, enGene is enabling its technology to be administered in several fashions - including oral, enema, inhalation and injection - to expand its potential applications into a broad array of diseases. The genesis of enGene s technology dates back to the 1970s when Dr. John C. Brown of UBC, a world-renowned researcher in gastrointestinal physiology, discovered the first incretin hormone called GIP (Glucose-dependent Insulinotropic Polypeptide) produced by K-cells in the gastrointestinal tract. Since that initial discovery, scientists have published findings that demonstrate that K-cells are very similar to the beta-cells that produce insulin, in that both are sensitive to glucose levels in the body and both secrete specific hormones in response to the level of glucose that is present. In 2000, two former students of Dr. Brown, Drs. Anthony Cheung and Timothy J. Kieffer, discovered a novel way to use Dr. Brown s research to treat diabetes. Drs. Cheung and Kieffer discovered how to coax K-cells to produce and secrete insulin in response to ambient glucose levels. The three scientists co-founded enGene to translate this idea into a medical product. In the initial years of the company, enGene s scientists focused their efforts on developing a safe and robust method to deliver genetic material to cells in the gut. After the company s scientists had refined the nucleotide delivery system to successfully induce K-cells in the gut to make insulin, they started to expand the technology into a nucleotide delivery platform to treat diseases of the gut and other mucosal tissues such as the lung, bladder and uterus. enGene s portfolio now encompasses a broad range of drug candidates drawing on its world-leading expertise in using biopolymers to deliver nucleotides.
EnGene is Vancouver-based company (British Columbia, Canada) with a phone number 604.221.4362. Our data show that the company is located at the address: 100-2386 East Mall. The company has a web site: www.engeneinc.com.
Unfortunately сompany staff has not yet provided of company's activities, mission and detailed description.